Inclusion criteria  ≥ 18 years of age Rutherford clinical stage 2 to 5 Atheromatous aorto-iliac lesions evidenced by duplex scan, CT angiography or arteriography. De novo atheromatous lesion of the aortoiliac segment Patient informed about the study and collection of the patient's informed consent agreement.  Exclusion criteria  Subjects will not be eligible to participate in the study if any of the following conditions are present in the subject:  Protected adult patients, guardianship, curatorship, safeguard of justice Woman with possibility of pregnancy Patient with asymptomatic atheromatous lesions Patient with inflow lesion in the infrarenal aorta Patient treated with Covered endovascular reconstruction of aortic bifurcation (CERAB reconstruction) Acute ischemia or acute thrombosis Non-atherosclerotic disease History of coagulopathy Severe comorbidities with life expectancy <2 years Contraindication to taking antiplatelet aggregation therapy (aspirin or clopidogrel). The patient must be able to take an antiplatelet aggregation for at least 3 months after the procedure Patient participating in another clinical study which may interfere with the results Comorbidity or any reason which, according to the investigator, could limit the participation, the patient's adherence with the follow-up or the scientific integrity of the study Lesion near or adjacent to an aneurysm Inability to follow-up during the trial Patient objection to participate in the trial